Maxcyte (MXCT) Depreciation & Amortization - Total (2024 - 2026)

Maxcyte (MXCT) has reported Depreciation & Amortization - Total for 3 consecutive years, with $961000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization - Total fell 11.75% year-over-year to $961000.0 in Q2 2026; TTM through Jun 2026 was $4.1 million, a 4.54% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 0.65% from the prior year.
• Depreciation & Amortization - Total was $961000.0 for Q2 2026 at Maxcyte, down from $1.0 million in the prior quarter.
• Over five years, Depreciation & Amortization - Total peaked at $1.1 million in Q2 2025 and troughed at $961000.0 in Q2 2026.
• A 3-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Depreciation & Amortization - Total.
• Across the five-year window, Depreciation & Amortization - Total rose 0.74% in 2025 and fell 11.75% in 2026, its largest moves.
• Over 3 years, Depreciation & Amortization - Total stood at $1.1 million in 2024, then fell by 0.19% to $1.1 million in 2025, then decreased by 8.91% to $961000.0 in 2026.
• The last three Depreciation & Amortization - Total figures came in at $961000.0 (Q2 2026), $1.0 million (Q1 2026), and $1.1 million (Q4 2025), per Business Quant data.